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CDX-1127 is a fully human antibody to CD27, a TNF
receptor superfamily member expressed on the majority
of T cells and subsets of NK cells and B cells. We have
previously characterized the co-stimulatory activities of
CDX-1127 with human T cell cultures and a human
CD27 transgenic mouse model (hCD27-Tg). Similar to
the findings originally shown by M.J. Glennie and col-
leagues using an agonist anti-mouse CD27 mAb, CDX-
1127 has potent antitumor activity as monotherapy in
several syngeneic tumor models in hCD27-Tg mice. In
the current studies, we sought to enhance the anti-
tumor efficacy of CDX-1127 in challenging tumor set-
tings by combination with clinically relevant therapies.
Specifically, we focused on therapies that could decrease
or control tumor growth while providing a source of
antigen to drive anti-tumor immunity (e.g. chemother-
apy or targeted therapy) and immune modifiers that
may allow the CD27 driven T cell response to overcome
self-regulation (e.g. checkpoint inhibitors or immune
activators). In the EG7 delayed treatment model (aver-
age tumor size of ~ 50 mm3 when treatment initiated),
the combination of CDX-1127 with cyclophosphamide
significantly improved survival (>70% survival) compared
to either agent alone (<30 % survival). Notably, we
found that the combination therapy was associated with
increases in the ratio of effector to regulatory T cells in
the tumors compared to either single agent group. Addi-
tional combination studies with various agents are on-
going, and initial studies with CDX-1127 combined with
anti-CTLA-4 mAb has shown superior anti-tumor activ-
ity (median survival 36.5 days in combination versus
20 days with either single agent). These studies, along
with the good safety profile of CDX-1127 reported in a
Phase 1 clinical trial, supports the design of future com-
bination studies in patients with cancer.
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